drugset
drugset / Trial / NCT05520827

A Study in Healthy Men to Test How Different Doses of BI 1584862 Are Tolerated and How BI 1584862 is Taken up in the Body With or Without Food

NCT05520827 ↗

Phase 1 Completed 77 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

Single Rising Dose (SRD) part: The main objectives of the SRD part of this trial are to investigate safety, tolerability, and pharmacokinetics (PK) of BI 1584862 in healthy male subjects following oral administration of single rising doses. Food Effect (FE) part: The main objective of the FE part is to assess the influence of food on the relative bioavailability of the BI 1584862 tablet.

Timeline

Start
2022-09-29
Primary completion
2023-03-06
Completion
2023-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1584862 Unknown — Oral

Indications

No indication recorded.